Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2018 Jul 1;39(1):5-13. doi: 10.2478/prilozi-2018-0019.

Authors

H K Aggarwal¹, Deepak Jain¹, Pulkit Chhabra², R K Yadav³

Affiliations

¹ Department of Medicine and Division of Nephrology Pt. B.D. Sharma University of Health Sciences, Rohtak(Haryana),India.
² Department of Medicine Pt. B.D. Sharma University of Health Sciences, Rohtak(Haryana),India.
³ Assistant Professor,Department of Nephrology, AIIMS New Delhi.

PMID: 30110263
DOI: 10.2478/prilozi-2018-0019

No abstract available

Keywords: Alendronate; Bisphosphonate; Chronic kidney disease; Osteoporosis.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Aged
Alendronate / adverse effects
Alendronate / pharmacology
Alendronate / therapeutic use*
Bone Density / drug effects*
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / pharmacology
Bone Density Conservation Agents / therapeutic use*
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Osteoporosis / chemically induced
Osteoporosis / drug therapy*
Renal Insufficiency, Chronic / drug therapy*
Renal Insufficiency, Chronic / physiopathology
Treatment Outcome
Young Adult

Substances

Bone Density Conservation Agents
Alendronate